Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162. doi:10.1097/JTO.000000000000003324419411
   PubMed Web of Science ®Google Scholar
• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–2911.26609494
   PubMed Web of Science ®Google Scholar
• Song X. Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. Onco Targets Ther. 2017;10:3119–3122. doi:10.2147/OTT.S13452328790845
   PubMed Web of Science ®Google Scholar
• Pan Y, Wang R, Ye T, et al. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014;145:473–479. doi:10.1378/chest.12-267924158231
   PubMed Web of Science ®Google Scholar
• Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. Thorac Oncol. 2017;12(4):612–623. doi:10.1016/j.jtho.2016.12.014
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa081069919692680
   PubMed Web of Science ®Google Scholar
• Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–1128. doi:10.1200/JCO.2011.36.845622370314
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334.23816960
   PubMed Web of Science ®Google Scholar
• Bironzo P, Di Maio M. A review of guidelines for lung cancer. J Thorac Dis. 2018;10:S1556–S1563. doi:10.21037/jtd29951306
   PubMed Web of Science ®Google Scholar
• Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503–2516. doi:10.1093/nar/17.7.25032785681
   PubMed Web of Science ®Google Scholar
• Chu H, Zhong C, Xue G, et al. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Oncol Rep. 2013;30(5):2311–2315. doi:10.3892/or.2013.270924002698
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–181. doi:10.1016/S1053-4296(03)00031-612903007
   PubMed Web of Science ®Google Scholar
• Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681–1690. doi:10.1093/annonc/mdu14524718890
   PubMed Web of Science ®Google Scholar
• Mascaux C, Tsao MS, Hirsch FR. Genomic testing in lung cancer: past, present, and future. J Natl Compr Canc Netw. 2018;16(3):323–334. doi:10.6004/jnccn.2017.701929523671
   PubMed Web of Science ®Google Scholar
• Miyamae Y, Shimizu K, Hirato J, et al. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep. 2011;25:921–928. doi:10.3892/or.2011.118221318227
   PubMed Web of Science ®Google Scholar
• Cho SH, Park LC, Ji JH, et al. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cancer Chemother Pharmacol. 2012;70:315–320. doi:10.1007/s00280-012-1876-022760226
   PubMed Web of Science ®Google Scholar
• Hata A, Katakami N, Yoshioka H, et al. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol. 2013;8:89–95. doi:10.1097/JTO.0b013e31827690b523242440
   PubMed Web of Science ®Google Scholar
• Joshi A, Zanwar S, Noronha V, et al. EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? Onco Targets Ther. 2017;10:1859–1863. doi:10.2147/OTT.S12539728405166
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhu L. Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients. BMC Cancer. 2015;15:88. doi:10.1186/s12885-015-1056-925886585
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang X, Qin N, et al. Detection and analysis of EGFR and KRAS mutations in the patients with lung squamous cell carcinomas. Zhongguo Fei Ai Za Zhi. 2015;18:621–625. doi:10.3779/j.issn.1009-3419.2015.10.0426483334
   PubMedGoogle Scholar
• Zhang T, Li J. Driven gene in patients with lung squamous cell carcinoma: analysis of clinicopathologic characteristics and prognosis. Zhongguo Fei Ai Za Zhi. 2016;19:648–652. doi:10.3779/j.issn.1009-3419.2016.10.0227760592
   PubMedGoogle Scholar
• Liu XP, Lu YC, Zhu GS, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol. 2013;66(12):1065–1069.23888061
   PubMed Web of Science ®Google Scholar
• Kang L, Zheng J, Zhu X. Relationship between EGFR mutations and pathological classification and specimen of lung adenocarcinoma. Zhongguo Fei Ai Za Zhi. 2017;20(6):382–388. doi:10.3779/j.issn.1009-3419.2017.06.0328641695
   PubMedGoogle Scholar
• Wang Z, Shen Z, Li Z, et al. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. Proc Natl Acad Sci U S A. 2015;112:9990–9995. doi:10.1073/pnas.151083711226216950
   PubMed Web of Science ®Google Scholar
• Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5:390–401. doi:10.1016/j.apsb.2015.07.00126579470
   PubMed Web of Science ®Google Scholar
• Duan J, Wang Z, Bai H, et al. Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung. Thorac Cancer. 2015;6:319–326. doi:10.1111/1759-7714.1220426273378
   PubMed Web of Science ®Google Scholar
• Felip E, Hirsh V, Popat S, et al. Symptom and quality of life improvement in LUX-Lung 8, an open-label phase III study of second-line afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung after first-line platinum-based chemotherapy. Clin Lung Cancer. 2017;19(1):74–83. doi:10.1016/j.cllc.2017.06.00228729180
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–550.25079552
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Y, Zhang L, et al. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: a multicenter study and pooled analysis of published reports. Oncotarget. 2017;8:49680–49688. doi:10.18632/oncotarget.1791528591695
   PubMedGoogle Scholar
• Xu J, Zhang Y, Jin B, et al. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. J Cancer Res Clin Oncol. 2016;142:1325–1330. doi:10.1007/s00432-016-2133-426942444
   PubMed Web of Science ®Google Scholar